Elisabeth Lackner

Elisabeth Lackner is an accomplished executive in the life sciences and healthcare sectors, currently serving as the Chief Executive Officer of CRS Clinical Research Services since March 2024, where Elisabeth oversees early-phase clinical trials. As a Senior Advisor at Arthur D. Little and Marinomed Biotech AG, as well as a self-employed consultant, Elisabeth provides strategic guidance in the healthcare and biotech fields. Elisabeth has held various leadership roles, including General Manager at D&A Pharma and Managing Director at GBA Gesellschaft für Bioanalytik mbH, and has significant experience in operations and business development, as evidenced by the objective of achieving 25% annual growth at Element Materials Technology. Elisabeth holds a PhD in Oncology and an MSc in Tumor Biology from the University of Vienna, along with a Mag.pharm in Pharmacy.